Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

被引:123
|
作者
McMullen, Michelle [1 ]
Karakasis, Katherine [1 ]
Madariaga, Ainhoa [1 ]
Oza, Amit M. [1 ]
机构
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Bras Family Drug Dev Program, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
关键词
resistance mechanisms; platinum; PARP; ovarian cancer; homologous recombination; REPLICATION FORK STABILITY; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; HOMOLOGOUS RECOMBINATION; MAINTENANCE THERAPY; REVERSION MUTATIONS; ACQUIRED-RESISTANCE; CLINICAL-OUTCOMES; EXCISION-REPAIR; MAMMARY-TUMORS;
D O I
10.3390/cancers12061607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on the intracellular DNA Damage Repair (DDR) response. Here, we review mechanisms of primary and acquired resistance to treatment with platinum and PARPi, examining the interplay between both classes of agents. A key resistance mechanism appears to be the restoration of the Homologous Recombination (HR) repair pathway, throughBRCAreversion mutations and epigenetic upregulation ofBRCA1.Alterations in non-homologous end-joint (NHEJ) repair, replication fork protection, upregulation of cellular drug efflux pumps, reduction in PARP1 activity and alterations to the tumour microenvironment have also been described. These resistance mechanisms reveal molecular vulnerabilities, which may be targeted to re-sensitise OC to platinum or PARPi treatment. Promising therapeutic strategies include ATR inhibition, epigenetic re-sensitisation through DNMT inhibition, cell cycle checkpoint inhibition, combination with anti-angiogenic therapy, BET inhibition and G-quadruplex stabilisation. Translational studies to elucidate mechanisms of treatment resistance should be incorporated into future clinical trials, as understanding these biologic mechanisms is crucial to developing new and effective therapeutic approaches in advanced OC.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [21] Combining PARP inhibitor with cMET Inhibition overcomes PARP inhibitor resistance in epithelial ovarian cancer
    Kim, Min-Je
    Lee, Shin-Wha
    Lee, Young-Jae
    Park, Su-Bin
    Kang, Dong-Woo
    Kim, Yong-Man
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer - Staging the aging
    Liposits, G.
    Lichtman, S. M.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 35
  • [23] A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
    Ceccaldi, Raphael
    O'Connor, Kevin W.
    Mouw, Kent W.
    Li, Adam Y.
    Matulonis, Ursula A.
    D'Andrea, Alan D.
    Konstantinopoulos, Panagiotis A.
    CANCER RESEARCH, 2015, 75 (04) : 628 - 634
  • [24] Overcoming platinum resistance in ovarian carcinoma
    Matsuo, Koji
    Lin, Yvonne G.
    Roman, Lynda D.
    Sood, Anil K.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (11) : 1339 - 1354
  • [25] Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
    Jazaeri, Amir A.
    Shibata, Etsuko
    Park, Jonghoon
    Bryant, Jennifer L.
    Conaway, Mark R.
    Modesitt, Susan C.
    Smith, Peter G.
    Milhollen, Michael A.
    Berger, Allison J.
    Dutta, Anindya
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) : 1958 - 1967
  • [26] Combining PARP inhibitor with TACC3 inhibition overcomes PARP inhibitor resistance in ovarian cancer
    Wu, Yu
    Wang, Qilong
    Deng, Chaolin
    Li, Mo
    Xiao, Yinan
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models
    Conlon, Neil T.
    Mohrle, Elena
    Stockmann, Luna
    Crown, John
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [28] Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer
    Tao, Mengyu
    Sun, Fan
    Wang, Juan
    Wang, Yujing
    Zhu, Hongrui
    Chen, Meiqi
    Liu, Liyun
    Liu, Li
    Lin, Houwen
    Wu, Xia
    PHARMACOLOGICAL RESEARCH, 2022, 179
  • [29] Efficacy of PARP-inhibitor for Chronic Myeloid Leukemia
    Ishii, Yuko
    Piao, Jinhua
    Takagi, Masatoshi
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S102 - S102
  • [30] PET imaging of PARP-inhibitor drug-target engagement predicts response in ovarian cancer in a pilot study
    Pantel, Austin
    Makvandi, Mehran
    Kim, Hyoung
    Weeks, Joanna
    Torigian, Drew
    Latif, Nawar
    Martin, Lainie
    Tanyi, Janos
    Morgan, Mark
    Doot, Robert
    Lin, Lilie
    Mankoff, David
    Mach, Robert
    Simpkins, Fiona
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63